Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer
Status In progress
Process STA 2018
ID number 1504

Provisional Schedule

Committee meeting: 1 02 October 2019
Expected publication 11 December 2019

Project Team

Project lead James Maskrey

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Key events during the development of the guidance:

Date Update
07 December 2018 Invitation to participate
16 October 2018 - 13 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance